Parameters | Valuea | Sources | Note | |
---|---|---|---|---|
Women | Men | |||
Cycle length one-year | ||||
one-year VF incidence | 0.06 | 0.02 | HIRA | NHI database |
one-year new VF incidence | 0.11 | 0.11 | [19] | Hospital cohort-NHI database linked data |
VFs treatment costa (€) | 1458 | 1509 | HIRA | NHI database |
Women aged 70 and older, men aged 80 and older | ||||
VF prevalence | 0.43 | 0.46 | [18] | Community-based cohort |
two-year VF incidence | 0.29 | 0.17 | HIRA | NHI database |
two-year new VF incidence | 0.32 | 0.32 | [19] | Hospital cohort-NHI database linked data |
RR of new VF on drug therapy | 0.60 | 0.60 | [33] | Meta-analysis, pooled RR |
Sensitivity of VFA | 0.88 | 0.88 | [34] | Diagnostic accuracy study for elderly adults |
Specificity of VFA | 0.99 | 0.99 | [34] | Diagnostic accuracy study for elderly adults |
VFs treatment costa (€) | 1513 | 1675 | HIRA | NHI database |